After pulling data from Benzinga Pro it seems like during Q2, Aquestive Therapeutics‘s (NASDAQ:AQST) reported sales totaled $15.35 million. Despite a 23.55% in earnings, the company posted a loss of $6.52 million. In Q1, Aquestive Therapeutics brought in $11.12 million in sales but lost $8.53 million in earnings.
Why ROCE Is Significant
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company’s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Aquestive Therapeutics posted an ROCE of 0.12%.
Keep in mind, while ROCE is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.
Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.
For Aquestive Therapeutics, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.
Analyst Predictions
Aquestive Therapeutics reported Q2 earnings per share at $-0.33/share, which beat analyst predictions of $-0.44/share.
